Research programme: protein kinase inhibitors - Millennium/Sunesis/Supernus

Drug Profile

Research programme: protein kinase inhibitors - Millennium/Sunesis/Supernus

Alternative Names: BIIB 024; SNS 229; SNS 510

Latest Information Update: 08 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Sunesis Pharmaceuticals; Takeda Oncology
  • Class Pyrazines; Small molecules; Thiazoles
  • Mechanism of Action 3 phosphoinositide dependent protein kinase 1 inhibitors; Protein kinase inhibitors; Proto oncogene protein b raf inhibitors; Raf kinase inhibitors; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Feb 2018 Sunesis Pharmaceuticals intends to file an IND application for SNS 510 in 2019
  • 08 Nov 2017 Preclinical development is ongoing in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top